- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Servier Acquires Day One Biopharmaceuticals | 8 | Contract Pharma | ||
| 23.04. | Servier completes the acquisition of Day One Biopharmaceuticals | 226 | PR Newswire | Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.04. | NSE - Day One Biopharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 23.04. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.04. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 13.03. | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 3.082 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| 11.03. | JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition | 5 | Investing.com | ||
| 10.03. | This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday | 2 | Benzinga.com | ||
| 09.03. | Servier acquires International Biotech's Day One Biopharmaceuticals for USD2.5 billion | 3 | Alliance News | ||
| 09.03. | Intnl. Biotechnology - Portfolio company Day One Biopharmaceuticals acquired by Servier | 1 | RNS | ||
| 07.03. | Key deals this week: Diana Shipping, Day One BioPharmaceuticals, Hudbay Minerals and more | 24 | Seeking Alpha | ||
| 07.03. | Day One Biopharmaceuticals (DAWN) Climbs to 3-Year High on $2.5-Billion Merger | 1 | Insider Monkey | ||
| 06.03. | Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma | 13 | MedCity News | ||
| 06.03. | Servier Acquiring Day One Biopharmaceuticals For About $2.5 Billion | 1 | pulse2.com | ||
| 06.03. | Servier Acquires Day One Biopharmaceuticals, Expanding Rare Oncology Portfolio | 2 | Contract Pharma | ||
| 06.03. | Servier to build cancer drug pipeline with $2.5B purchase of Day One Biopharmaceuticals | 1 | BioPharma Dive | ||
| 06.03. | Oppenheimer reiterates Day One Biopharmaceuticals stock rating on Servier deal | 2 | Investing.com | ||
| 06.03. | TD Cowen downgrades Day One Biopharmaceuticals stock on Servier deal | 3 | Investing.com | ||
| 06.03. | Jones Trading cuts Day One Biopharmaceuticals stock rating on Servier acquisition | 1 | Investing.com | ||
| 06.03. | Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday | 5 | Benzinga.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,00 | +2,30 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| AMGEN | 297,25 | +2,69 % | Did Amgen's Subsidiary Manipulate Data To Secure Tavneos Approval? | THOUSAND OAKS (dpa-AFX) - It takes 10-15 years and billions of dollars for a pharma company to bring a drug to the market. Now imagine that after years of effort, time, and investment, a company... ► Artikel lesen | |
| NOVAVAX | 7,040 | +2,92 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 163,18 | -2,04 % | Aktien New York Ausblick: Wenig Bewegung vor Zinsentscheid und Tech-Zahlen | NEW YORK (dpa-AFX) - An den US-Börsen zeichnet sich zur Wochenmitte eine uneinheitliche, aber insgesamt wenig bewegte Eröffnung ab. Im Fokus stehen die erst nach Börsenschluss angekündigten Quartalszahlen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,780 | +0,77 % | What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. | ||
| VIKING THERAPEUTICS | 25,000 | -6,89 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,800 | +10,69 % | Intellia Therapeutics prices $180M stock offering at discount | ||
| TEMPUS AI | 46,670 | +8,97 % | Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy? | ||
| BIOCRYST PHARMACEUTICALS | 7,746 | +0,65 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,680 | +0,56 % | BioMarin Pharmaceutical Inc.: BioMarin Completes Acquisition of Amicus Therapeutics | Acquisition Adds Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease to BioMarin's Commercial... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,380 | -1,92 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| EXELIXIS | 38,815 | +1,40 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | -1,08 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| CARDIOL THERAPEUTICS | 1,144 | +1,60 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart adds James Breitmeyer to board of directors |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,045 (+0,21 %) liegt der Kurs bei 21,530 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.